A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
This is an extension study to evaluate the safety of Veliparib monotherapy or in combination with Carboplatin plus Paclitaxel or modified Folinic Acid/Fluorouracil/Irinotecan (FOLFIRI) in subjects with solid tumors.
Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors
DRUG: Veliparib|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: FOLFIRI
Number of subjects with adverse events, Measured up to 30 days after the last dose of study drug.
Objective Response Rate (ORR), Radiographic evaluation at Screening and every 6-9 weeks until the final visit, up to 18 months.|Overall Survival (OS), Every 3 months after the subject is registered off study up to 2 years post discontinuation or until date of death from any cause, whichever comes first.|Time to Disease Progression (TTP), Assessed at each visit up to 18 months after the last subject has enrolled in the study.|Progression Free Survival (PFS), Radiographic evaluation starting from the first day of study drug until documented progression or date of death, whichever comes first, until the subject is registered off study.|Clinical Laboratory Tests, Hematology, Chemistry, Urinalysis, Up to 18 months.|Electrocardiogram, Up to 18 months.|Tumor Assessment, A computerized tomography scan to document the size of the tumor., Up to 18 months.
This is an extension study to evaluate the safety of Veliparib monotherapy or in combination with Carboplatin plus Paclitaxel or modified Folinic Acid/Fluorouracil/Irinotecan (FOLFIRI) in subjects with solid tumors.